Aceragen (IDRA) – Press Releases
-
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
-
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Acquires Aceragen
-
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
-
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
-
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Announces Tilsotolimod Updates
-
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Announces Corporate Updates
-
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
Vyant Bio Announces Newly Appointed Board of Directors
-
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
-
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals to Present at Upcoming Conferences
-
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
-
Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
-
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
-
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
-
Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
-
Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer
-
Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders
-
Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
-
Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma
-
Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million
-
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma
-
Idera Pharmaceuticals Provides 2020 Update and Outlook
-
Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million
-
Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results
-
Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037
-
Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
-
Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie
-
Idera Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference
-
Idera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial Results
-
Idera to Release 2019 Second Quarter Results on August 8, 2019
-
Idera Pharmaceuticals Announces Appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and John J. Kirby as Chief Financial Officer
-
Idera Pharmaceuticals to Present at the 2019 JMP Securities Life Sciences Conference
-
Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
-
Repare Therapeutics Appoints Dr. Maria Koehler as Chief Medical Officer, Katina Dorton as Chief Financial Officer and Carol Schafer to its Board of Directors
-
Idera Pharmaceuticals Provides Corporate Update
-
Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association
-
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
-
Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor T
-
Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors
Back to IDRA Stock Lookup
